Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Pyxis Oncology Inc. Common Stock
PYXS | US
3.68
USD-0.07
-1.87%
PYXS | US
About Pyxis Oncology Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
3.68
Open
3.76
High
4.19
Low
3.66
Pyxis Oncology Inc. a clinical-stage biopharmaceutical company engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106 an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody which is in Phase 1 clinical trial for the treatment of solid tumors including non-small cell lung cancer (NSCLC) without driver mutations/translocations breast cancer endometrial cancer thyroid cancer kidney cancer cholangiocarcinoma bladder cancer colorectal cancer and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201 an investigational human immunoglobulin G1 isotype site-specifically conjugated which is in Phase 1 clinical trial for solid tumors including NSCLC hormone receptor-positive breast cancer ovarian cancer thyroid cancer pancreatic ductal adenocarcinoma soft tissue sarcoma hepatocellular carcinoma and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge Massachusetts.
View LessPYXS | US
Risk
74.2
Sharpe
1.06
Luna's Score
46/100
Recommendation
Hold
Luna says (PYXS | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
90.3%1 month
74.2%3 months
68.8%6 months
64.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.31
Debt to equity
0.12
Debt to assets
0.10
Ent. to EBITDA
1.09
Ent. to rev.
5.45
PEG
-
Other Fundamentals
EBITDA
-63.16M
MarketCap
218.68M
MarketCap(USD)
218.68M
Div. yield
-
Op. margin
-409.25
Erngs. growth
-
Rev. growth
-
Ret. on equity
-37.58
Short ratio
8.84
Short perc.
8.63
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.19
Range1M
1.19
Range3M
1.19
Volumes: Market Activity
Rel. volume
3.55
Price X volume
7.33M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.09 | 0.53 | Expensive |
| Ent. to Revenue | 5.45 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.31 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 68.84 | 72.80 | Par |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 218.68M | 3.66B | Emerging |
